July 25, 2017Open Access

Mutacões HER2 em adenocarcinomas pulmonares: Um relatório do Lung Cancer Mutation Consortium

Key Points

Key points are not available for this paper at this time.

Abstract

Mutacões HER2 foram detectadas em 3% dos pacientes com adenocarcinoma pulmonar no LCMC. Terapias direcionadas a HER2 devem ser investigadas neste subgrupo de pacientes. Cancer 2017;123:4099-4105. © 2017 American Cancer Society.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Rathi N. Pillai

Madhusmita Behera

Lynne D. Berry

Journals

Cancer

Actions

Institutions

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

Emory University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Mutacões HER2 em adenocarcinomas pulmonares: Um relatório do Lung Cancer Mutation Consortium

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study